Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors

Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking. The advent of radiomics and pathomics offers new avenues for refining neoadju...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiayi Wang, Jiahui Dai, Yangxi Cheng, Xirui Wang, Rui Deng, Huiyong Zhu
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Translational Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325001664
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849694494883053568
author Jiayi Wang
Jiahui Dai
Yangxi Cheng
Xirui Wang
Rui Deng
Huiyong Zhu
author_facet Jiayi Wang
Jiahui Dai
Yangxi Cheng
Xirui Wang
Rui Deng
Huiyong Zhu
author_sort Jiayi Wang
collection DOAJ
description Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking. The advent of radiomics and pathomics offers new avenues for refining neoadjuvant therapy strategies and could provide high-performance predictive tools. The integration of multi-omics represents an emerging area of research. The introduction of radiopathomics offers innovative approaches to studying the efficacy of neoadjuvant therapy. This article reviews the current developments in multi-omics integration, the advances in the use of radiopathomics to predict the efficacy of neoadjuvant therapy, and the challenges faced by ongoing research.
format Article
id doaj-art-eea930377ca141998f7496f32a885831
institution DOAJ
issn 1936-5233
language English
publishDate 2025-08-01
publisher Elsevier
record_format Article
series Translational Oncology
spelling doaj-art-eea930377ca141998f7496f32a8858312025-08-20T03:20:03ZengElsevierTranslational Oncology1936-52332025-08-015810243510.1016/j.tranon.2025.102435Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumorsJiayi Wang0Jiahui Dai1Yangxi Cheng2Xirui Wang3Rui Deng4Huiyong Zhu5Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; School of Medicine, Zhejiang University, Hangzhou 310058, ChinaDepartment of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; School of Medicine, Zhejiang University, Hangzhou 310058, ChinaDepartment of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; School of Medicine, Zhejiang University, Hangzhou 310058, ChinaDepartment of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; School of Medicine, Zhejiang University, Hangzhou 310058, ChinaDepartment of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; School of Medicine, Zhejiang University, Hangzhou 310058, ChinaDepartment of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Corresponding author.Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking. The advent of radiomics and pathomics offers new avenues for refining neoadjuvant therapy strategies and could provide high-performance predictive tools. The integration of multi-omics represents an emerging area of research. The introduction of radiopathomics offers innovative approaches to studying the efficacy of neoadjuvant therapy. This article reviews the current developments in multi-omics integration, the advances in the use of radiopathomics to predict the efficacy of neoadjuvant therapy, and the challenges faced by ongoing research.http://www.sciencedirect.com/science/article/pii/S1936523325001664RadiomicsPathomicsMulti-omicsNeoadjuvant therapyEfficacy
spellingShingle Jiayi Wang
Jiahui Dai
Yangxi Cheng
Xirui Wang
Rui Deng
Huiyong Zhu
Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors
Translational Oncology
Radiomics
Pathomics
Multi-omics
Neoadjuvant therapy
Efficacy
title Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors
title_full Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors
title_fullStr Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors
title_full_unstemmed Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors
title_short Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors
title_sort advances in the use of radiomics and pathomics for predicting the efficacy of neoadjuvant therapy in tumors
topic Radiomics
Pathomics
Multi-omics
Neoadjuvant therapy
Efficacy
url http://www.sciencedirect.com/science/article/pii/S1936523325001664
work_keys_str_mv AT jiayiwang advancesintheuseofradiomicsandpathomicsforpredictingtheefficacyofneoadjuvanttherapyintumors
AT jiahuidai advancesintheuseofradiomicsandpathomicsforpredictingtheefficacyofneoadjuvanttherapyintumors
AT yangxicheng advancesintheuseofradiomicsandpathomicsforpredictingtheefficacyofneoadjuvanttherapyintumors
AT xiruiwang advancesintheuseofradiomicsandpathomicsforpredictingtheefficacyofneoadjuvanttherapyintumors
AT ruideng advancesintheuseofradiomicsandpathomicsforpredictingtheefficacyofneoadjuvanttherapyintumors
AT huiyongzhu advancesintheuseofradiomicsandpathomicsforpredictingtheefficacyofneoadjuvanttherapyintumors